AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate
Completed
- Conditions
- Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 301
- Registration Number
- NCT04814680
- Locations
- 🇰🇪
Research Site, Nairobi, Kenya
A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)
Completed
- Conditions
- Asthma
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT04808518
- Locations
- 🇯🇵
Research Site, Yonago, Japan
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 798
- Registration Number
- NCT04807595
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 748
- Registration Number
- NCT04808050
- Locations
- 🇦🇪
Research Site, Alain, United Arab Emirates
Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis
Completed
- Conditions
- HyperkalemiaWater-Electrolyte ImbalanceHemodialysis
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT04799067
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
Completed
- Conditions
- Metastatic Castration-resistant Prostates Cancer
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1920
- Registration Number
- NCT04801186
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment CDrug: Treatment GDrug: Treatment HDrug: Treatment E
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT04798222
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
Phase 1
Completed
- Conditions
- Hyperkalaemia
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04788641
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer; HER2-positive; Metastatic
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1157
- Registration Number
- NCT04784715
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 152
- Registration Number
- NCT04774380
- Locations
- 🇹🇷
Research Site, Pamukkale, Turkey
© Copyright 2025. All Rights Reserved by MedPath